Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy

Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy

Abstract Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years. T...

Full description

Saved in:
Bibliographic Details
Main Authors: Shigeo Ohba, Takao Teranishi, Kazuyasu Matsumura, Masanobu Kumon, Daijiro Kojima, Eiji Fujiwara, Kazutaka Nakao, Kiyonori Kuwahara, Kazuhiro Murayama, Eriel Sandika Pareira, Seiji Yamada, Masahiro Joko, Shunsuke Nakae, Jun Muto, Yuya Nishiyama, Kazuhide Adachi, Hikaru Sasaki, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Glioblastoma
Karnofsky Performance Status
MGMT
Radiotherapy
Temozolomide
Tumor size
Online Access:https://doi.org/10.1038/s41598-025-85339-x
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years. This study aimed to identify the factors associated with survival time with maintenance of KPS ≥ 50% (survival with KPS ≥ 50%) in patients with glioblastoma, IDH-wildtype. Ninety-eight patients with glioblastomas, IDH-wildtype, who were treated with concomitant radiotherapy (RT) and temozolomide (TMZ) followed by maintenance TMZ therapy, and whose KPS at the start of RT was ≥ 50%, were included. The median survival with KPS ≥ 50% was 13.3 months. In univariate analysis, preoperative KPS (≥ 80%), KPS at the start of RT (≥ 80%), residual tumor size (< 2 cm3), methylated MGMT promotor, and implantation of BCNU wafer were associated with survival with KPS ≥ 50%. In multivariate analysis, KPS at the start of RT (≥ 80%), methylated MGMT promotor, and residual tumor size (< 2 cm3) were significantly associated with increased survival with KPS ≥ 50%. A strategy of maximum possible tumor resection without compromising KPS is desirable to prolong the survival time with KPS ≥ 50%.
ISSN:2045-2322

Similar Items